TrialHaematologica2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Johannes Duell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
69 papers cite itlatest 60 shown
this paperpooled ittrialcites it